In this report we describe an experimental model of cachexia that fulfills the criteria of an early effect with a small tumor mass not related to the growth rate of the tumor, and progressive wasting of muscle and fat without a detectable loss of appetite. C-26.IVX is a cell line derived from murine colon-26 adenocarcinoma which retains the transplantability of the original tumor and induces true cachexia in syngeneic hosts. Evidence is presented to support a role for interleukin (IL-6) as a cachectic factor in the development of cancer cachexia in this model system. Thus, increasing levels of IL-6 in C-26.IVX-bearing mice correlate with the development of cachexia. If the primary tumors were resected, mice gained weight and the levels ofIL-6 in the serum were reduced significantly. Moreover, monoclonal antibody to murine IL-6 (but not anti-tumor necrosis factor antibody) was able to significantly suppress the development of key parameters of cachexia in tumor bearing mice. (J. Clin.
Introduction
Cancer cachexia, which includes depletion of muscle and fat tissue, anorexia, asthenia, hypoglycemia and anemia (1, 2) , complicates therapeutic intervention (3) and is an important cause of death in cancer patients (4) . Host-derived and tumor cell-derived tumor necrosis factor (TNF)' has been suggested as a mediator of the metabolic changes associated with cachexia because it can suppress key metabolic enzymes and can induce cachexia in experimental animals (5-7). However, extrapolation ofthese findings to clinical cancer has been difficult and yields mixed results (8) (9) (10) . Thus the precise mechanism of cancer cachexia remains largely unknown (4, 1 1).
Only few animal transplantable tumors are capable of inducing cachexia in vivo (12) . Even fewer of the experimental models that have been used to study the mechanism of cachexia fulfill the criteria that cachexia should be an early effect of the tumor and be present with a small tumor burden (4, 12) . Instead, cachexia is usually studied in rapidly growing rodent tumors which appear as a late effect usually just before death when the tumor mass has grown to a large size. These models attribute the cachexia to a decrease in food intake and competition of the tumor with the host for essential nutrients. Such tumor models are thus not indicative of the conditions of cancer patients with cachexia (4, 12) .
Murine colon-26 adenocarcinoma is an undifferentiated tumor induced by a carcinogen (N-nitroso-N-methylurethan) and has been shown to induce cachexia in mice (12, 13 Cytokine assays. IL-6 was determined using IL-6-dependent B-9 cells as described (14) . 1 U of IL-6 was defined as the amount required for half-maximal stimulation ofcell proliferation in the assay. Addition of anti-IL-6 monoclonal antibody completely abolished cell proliferation in this assay (data not shown). Total TNF was determined in the L929 bioassay as described (14) and an ELISA as described (15) . The lowest detectable level of murine TNF-a was 30 pg/ml in the bioassay and 15 pg/ml in the ELISA.
Total IL-1 was determined by a radioreceptor assay as described (14) , using endotoxin-induced macrophage-conditioned medium and human recombinant IL-1(I ( 18 (Fig. 1) . Several physiological changes associated with cachexia were also monitored. Hypoglycemia started ca. day 12, when body wasting was still slight, and glucose levels fell to less than half of their control levels by day 18 whereas the concentration of acutephase proteins in the blood, such as SAP, were significantly elevated (Table I) . A significant decrease in the weights ofheart and liver tissue as well as gastrocnemius muscle was observed in C-26-bearing mice (Table I) . It is unlikely that the rapid wasting of body tissue in the mice bearing C-26.IVX cells was due to anorexia, because food intake was not reduced while they were losing weight. Thus, between days 11 to 18 postinoculation, the cumulative food intake of the C-26.IVX-bearing mice (49 g) was similar to that of the non-tumor-bearing controls (50 g). Diarrhea or other evidence of malabsorption were not observed in C-26-bearing mice. In addition, piloerection and asthenia were observed only in mice bearing C-26.IVX. Taken together these observations suggest that the C-26.IVXbearing mouse is an appropriate model for cancer cachexia.
Next, we tested the production of possible mediators of cachexia in this model. To our surprise, TNF-a and IL-1 could not be detected in either the conditioned medium of colon-26 tumor or in the C-26.IVX line. Furthermore, TNF-a was not detectable in the serum of mice bearing the tumor while they were developing progressive cachexia. On the other hand, high levels of IL-6 could be identified in colon-26 tumor-conditioned medium as well as in the serum of C-26.IVX-bearing mice (Table II) . IL-6 was detected in C-26.IVX tissue culture supernatant, although at a level -60-fold lower than in the tumor. In further experiments we found that the tumor is contaminated with up to 6% of host-derived macrophages. The interaction between tumor cells and host macrophages is responsible for the elevated IL-6 produced by the tumor (data not shown).
When the C-26.IVX line was transplanted into mice, a correlation between the magnitude of weight loss and the appearance ofIL-6 in the circulation was found (Table II) . To test the possibility of IL-6 as a cachectic factor we attempted to inhibit the action of IL-6 with neutralizing anti-murine IL-6 monoclonal antibody, and were able to demonstrate that inhibition of IL-6 activity abolished the C-26.IVX induced cachexia.
MP5-20F3 is a rat IgG, anti-mouse IL-6 neutralizing monoclonal antibody which is a potent and specific antagonist of mouse IL-6 bioactivity (17). Anti-IL-6 pretreatment of mice subsequently challenged with lethal doses of Escherichia coli infection protects mice from death (17) . Monoclonal TN3. 19.12 is a hamster anti-murine TNF antibody that reacts with both TNF-a and TNF-3 and has been shown to neutralize TNF activities in vivo (15, 18) , and at the amounts used here the antibody completely blocked LPS-induced hypertrygliceridemia (not shown). Age-matched mice were randomized to receive an injection of 0.5 x 106 C-26.IVX cells. On days 6 and 12 after tumor inoculation, mice received either PBS or monoclonal antibody against murine IL-6 (1 mg/mouse per injection) or monoclonal anti-murine TNF neutralizing antibody (0.5 mg/mouse per injection). Animals were killed on day 16. As shown in Table  III , experiment 1, anti-IL-6 but not anti-TNF antibody was able to significantly suppress the development of cachexia as is evident from comparison of body compositional analysis. Whereas carcass weight and epididymal fat was significantly increased by anti-IL-6 treatment, tumor weight was not changed, indicating that this treatment affected the host directly. Daily measurements oftotal weight (from day 12 to day 16), did not reveal any difference between C-26-bearing mice treated with anti-IL-6 monoclonal antibody and age-matched controls (data not shown).
Moreover, in a separate experiment also depicted in Table  III , the reversal of various metabolic parameters of cachexia by anti-IL-6 antibodies parallel the reduction in the level of IL-6 in the serum of treated mice. No such effect could be seen in tumor-bearing mice treated with a nonrelevant rat IgG antibody. In addition, after the primary tumor was resected on day 15, the mice gained weight, piloerection and asthenia disappeared, and IL-6 levels in the serum were reduced significantly within 5 d (Table IV) . In conclusion, three lines of evidence support the role of IL-6 as an important cachectic factor in the development of cancer cachexia: (a) measurable circulatory levels ofIL-6 can be identified in colon-26-bearing mice; (b) the serum level of IL-6 correlates with the degree of cachexia; Tumor-bearing mice were randomized to receive intraperitoneally PBS or MP5-20F3 (1 mg/0.5 ml per mouse), or TN3.19.12 (0.5 mg/0.5 ml per mouse), or purified rat IgG (1 mg/0.5 ml per mouse), respectively. In experiment 1 treatment was given on days 6 and 12 post-C-26.IVX cell inoculation (as described in Fig. 1) , and animals were killed on day 16, whereas in experiment 2 the various treatments were administered on days 7 and 13 after inoculation of C-26.IVX cells, and animals were killed on day 17. Cachectic markers were quantified as described in Methods. P values for statistical significance of the results obtained in group 3 vs. groups 1 and 2 are given. No statistical difference of total weight, carcass weight, and dry weight between groups 3 and 4 in experiment 2 could be observed. Mice were inoculated with C-26.IVX cells as described in the legend to Fig. 1 . On day 15 mice were anesthetized and the entire tumor mass was resected. Age-matched control mice received a sham operation. Weight of animals was monitored daily. Serum IL-6 levels were determined as described in Methods. * P = 0.005. * NS.
(c) inhibition of the action of IL-6 abolishes key parameters of cachexia including muscle and fat wasting, hypoglycemia, and hepatic acute-phase response.
The integral role of IL-6 in stimulating hepatic acute-phase response (19) , which is frequently seen in cancer patients (20) , the fact that elevated levels of IL-6 circulate in the serum of tumor-bearing mice (21) , and the recent report on the decrease in body weight of nude mice given IL-6-transfected Chinese hamster ovary cells (22) corroborate the data presented here in supporting a major role for IL-6 in clinical cancer cachexia. In addition, alterations in lipid metabolism resulting in depletion of host body fat is believed to involve the suppression of the enzyme lipoprotein lipase and appears to be a hallmark ofclinical cancer cachexia (2) . Several cytokines including TNF, IL-1, and IL-6 have been implicated as participants in cachexia because they mediate hepatic lipogenesis and inhibit lipoprotein lipase activity (2, 23, 24) . TNF does not appear to play a central role in C-26-induced cachexia. However, TNF has been shown to participate in weight loss associated with anorexia (25) . Because C-26-bearing mice are not anorectic, the fact that TNF seems not to be involved is not surprising. Recently, treatment of tumor-bearing rats with antibody against IFN-'y but not with antibody against TNF was shown to partially reverse some cachectic changes associated with cancer (26) . Because IL-1, TNF, and IFN-'y are known to stimulate or to serve as a cosignal for IL-6 production (19, 27) and because IL-6 also mediates some ofthe actions ofTNF and IL-1 in vivo (21) , it is possible that IL-6 is a common mediator involved in cachectic events in many, if not all, experimental cachexia models.
Whether IL-6 is a mediator common to all clinical cancer cachexia or just to certain types of cancer remains to be established. Furthermore, our work suggests that specific strategies to attempt to remove or neutralize IL-6 activity in cancer patients will likely improve antitumor treatment.
